Treatment of Catatonia With Olanzapine and Amantadine
Department of Psychiatry and Behavioral Sciences, Eastern Virginia Medical School, Norfolk, Virginia, United States Psychosomatics
(Impact Factor: 1.86).
11/2007; 48(6):534-6. DOI: 10.1176/appi.psy.48.6.534
Catatonia is a disorder characterized by mutism, posturing, echophenomena, and negativism. The preferred treatment for non-malignant catatonia is benzodiazepines, which often produce a reduction in symptoms within 24 hours. Presented here is a case report of a 19-year-old woman appearing in a catatonic state that did not respond to lorazepam. On the basis of emerging evidence that atypical antipsychotics and weak N-Methyl-D-Aspartate (NMDA) receptor-antagonists may effectively treat catatonia, we treated our patient with olanzapine and amantadine, which resulted in a dramatic reduction in her catatonic symptoms.
Available from: Ayse Kilincaslan
- "Another hypothesis related to pathophysiology of catatonia is the inhibition of the D2 receptors (Philbrick and Rummons 1994). Catatonia can be induced with atypical antipsychotics, although they have actually been found to be effective in the treatment of catatonia (Kopala and Caudle 1998; Duggal and Gandotra 2005; Babington and Spiegel 2007; Guzman et al. 2008). These studies suggest that dopamine regulation can be important in the treatment of catatonia. "
Journal of child and adolescent psychopharmacology 06/2010; 20(3):225-7. DOI:10.1089/cap.2009.0046 · 2.93 Impact Factor
Available from: Shao-Tsu Chen
- "But our patient did not respond to lorazepam within 2 h. Recently, increasing reports on the use of atypical antipsychotics such as olanzapine may indicate their utility in treating some varieties of catatonia (Babington and Spiegel, 2007; Cassidy et al., 2001; DelBello et al., 2000; Dudova and Hrdlicka, 2008; Guzman et al., 2008; Nicolato et al., 2006; Tan et al., 2006). (Table 1) Moreover, olanzapine may increase appetite (Bhana et al., 2001) to improve his poor intake. "
Progress in Neuro-Psychopharmacology and Biological Psychiatry 10/2009; 33(8):1559-60. DOI:10.1016/j.pnpbp.2009.08.018 · 3.69 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Narcolepsy and schizophrenia are disorders which share common features of negative symptoms, excessive daytime sleepiness and cognitive deficits. Presented here is a case report of a fifty-nine year old man with a past medical history of schizophrenia who was evaluated for suspected symptoms of delirium. After an electroencephalogram was performed with surprising results, the patient's differential diagnosis included schizophrenia with comorbid narcolepsy. We present emerging evidence that excessive daytime sleepiness and attentional deficits in both narcolepsy and schizophrenia may share a common pathophysiological. pathway through orexin deficiency and its effects on the dopamine system. Finally, we discuss the potential for modafinil as a treatment for excessive daytime sleepiness and attentional problems in schizophrenia and narcolepsy.
Clinical Schizophrenia & Related Psychoses 10/2008; 2(3):255-258. DOI:10.3371/CSRP.2.3.6
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.